Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early topical cyclosporine for prevention of ocular graft-versus-host disease after allogeneic stem cell transplantation
NL-OMON28561Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2010
- Modality
- Small Molecules, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial in graft versus host disease (GVHD) comparing Restasis prophylaxis with Vidisic control (2 arms). Primary endpoints: Occurrence of ocular graft-versus-host disease, Severity of ocular graft-versus-host disease and 1 more. Planned start Apr 2010; status: not yet recruiting.
02
Drugs
cyclosporinecarbomer
03
Conditions
graft versus host disease (GVHD)
Beyond the preview
Go deeper on NL-OMON28561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28561.